This is an exciting time in bioprocessing, as the biopharma industry is adapting rapidly to tackle global healthcare challenges. New modalities offer novel solutions for therapeutics and vaccines, while traditional bioprocessing is evolving with new technology platforms that enable data visualization, analytics, and process monitoring.
Animal-derived cells have been used successfully to produce biopharmaceuticals, such as monoclonal antibodies and recombinant proteins, since the 1980s. Since production templates depend on cell culture processes, they are susceptible to contamination by adventitious agents, such as bacteria and viruses.
Viral contamination of biopharmaceutical processes is particularly challenging, for contaminants may be present at levels below the sensitivity of test methods. If contamination is present, it may persist from the cell culture process into downstream operations and have severe consequences for both the aﬀected companies and the patients that rely on their drugs.
Whether you are a newcomer or an experienced biomanufacturer, explore a holistic overview of viral safety that consolidates decades of expertise and process understanding from technical experts.